PN summer web series kicks off in July! Learn more
diabetic peripheral neuropathy treatment

Research Study for Painful Diabetic Peripheral Neuropathy

Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy and Safety of NYX-2925 in Subjects with Neuropathic Pain Associated with Diabetic Peripheral Neuropathy.

Aptinyx Inc. is conducting a research study evaluating multiple doses of its investigational drug NYX-2925 versus placebo in treating the neuropathic pain associated with diabetic peripheral neuropathy. Enrollment into this study will run from July 2017, through October 2018. Subjects will participate in the trial from six to nine weeks.

NYX-2925 is an investigational drug that is being studied for treatment of nerve pain associated with diabetic peripheral neuropathy and for fibromyalgia. Evaluations include questions about your pain level, medications, and your overall well-being. Qualified patients will receive all investigational study drugs at no cost, study-related care from the study doctor at no cost, and possibly compensation for time and travel.

You may be qualified to join this research study if you are:

  • Type 2 diabetic
  • Diagnosed with painful diabetic peripheral neuropathy or experiencing diabetic peripheral neuropathy pain in both feet/legs for at least 6 months and not longer than 10 years
  • Age 18-75 years old
  • On stable medication(s) for pain
  • On stable medication(s) for diabetes or diabetes controlled on diet and exercise alone

You may not participate in this research study if you have:

  • Schizophrenia, bipolar disorder, or panic disorder
  • Significant kidney, liver, heart, or vascular disease
  • Huntington’s disease, Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, or a history of seizures, epilepsy, or strokes
  • Amputation of lower extremities (toe amputation is allowed)

Other requirements:

  • Commit to daily online diary entries for up to 9 weeks
  • Complete study visits and follow-up phone calls
  • Take and store study medication and rescue medication as instructed
  • Follow instructions regarding acceptable birth control methods, if applicable
  • Follow instructions of the study doctor/staff

The research study is being conducted at the following locations:

  • Anaheim, California, United States, 92801
  • Fresno, California, United States, 93710
  • Norco, California, United States, 92860
  • Tustin, California, United States, 92480
  • New London, Connecticut, United States, 06320
  • Bradenton, Florida, United States, 34201
  • Brandon, Florida, United States, 33511
  • Fort Myers, Florida, United States, 33912
  • Hallandale Beach, Florida, United States, 33009
  • Miami, Florida, United States, 33012
  • Miami, Florida, United States, 33126
  • Miami, Florida, United States, 33175
  • Ocoee, Florida, United States, 34761
  • Orlando, Florida, United States, 32801
  • Orlando, Florida, United States, 32806
  • Tampa, Florida, United States, 33603
  • West Palm Beach, Florida, United States, 33401
  • Columbus, Georgia, United States, 31904
  • Decatur, Georgia, United States, 30033
  • Chicago, Illinois, United States, 60640
  • Flossmoor, Illinois, United States, 60422
  • Hazelwood, Missouri, United States, 63042
  • Berlin, New Jersey, United States, 08009
  • Dayton, Ohio, United States, 45439
  • Knoxville, Tennessee, United States, 37909
  • Memphis, Tennessee, United States, 38119
  • Tullahoma, Tennessee, United States, 37388
  • Austin, Texas, United States, 78731
  • Houston, Texas, United States, 77058
  • Plano, Texas, United States, 75024
  • Plano, Texas, United States, 75093
  • Norfolk, Virginia, United States, 23510

To find out more information about this research study or to find a study location near you, please visit or call Acurian (agent for Aptinyx Inc.) at 855-452-8072.

This research study is also posted on the site. Click here to read more.

To find out more about other clinical trials being offered to peripheral neuropathy patients, please go to the Foundation for Peripheral Neuropathy’s Clinical Trials website.

Leave a Comment